NHS foundation trust

Aktana Announces Release of Next Generation Omnichannel Orchestration Tools Designed for Medical Technology Companies

Retrieved on: 
Tuesday, March 5, 2024

“However, less than 20% of MedTech companies are using advanced omnichannel capabilities.

Key Points: 
  • “However, less than 20% of MedTech companies are using advanced omnichannel capabilities.
  • Aktana for MedTech is comprised of Aktana’s world-class open platform, Field Orchestrator, Omnichannel Orchestrator, Analytics Activator, as well as Copilot Mobile.
  • Specifically, Aktana for MedTech:
    Allows medical technology companies to simplify scheduling, manage stock, optimize inventory utilization and streamline procurement processes with AI-powered omnichannel orchestration.
  • Today, commercial and medical teams from more than 350 brands use Aktana’s next generation-AI complete orchestration to deliver personalized omnichannel engagement at scale.

Aleta Biotherapeutics and Cancer Research UK’s Centre for Drug Development Announce First Patient Dosed in ALETA-001 Phase 1/2 Clinical Trial in Patients with Relapsed/Refractory B-Cell Malignancies

Retrieved on: 
Wednesday, February 21, 2024

Aleta Biotherapeutics (Aleta), a clinical stage, immuno-oncology company with a CAR T-Cell Engager (CTE) platform that enables cell cancer therapies to work more effectively, and Cancer Research UK’s Centre for Drug Development, today announce the first patient was dosed in a Phase 1/2 clinical trial.

Key Points: 
  • Aleta Biotherapeutics (Aleta), a clinical stage, immuno-oncology company with a CAR T-Cell Engager (CTE) platform that enables cell cancer therapies to work more effectively, and Cancer Research UK’s Centre for Drug Development, today announce the first patient was dosed in a Phase 1/2 clinical trial.
  • This trial is evaluating the Company’s first-in-class biologic CAR T-Cell Engager, ALETA-001, for the treatment of patients with B-cell malignancies who are relapsed/refractory to CD19-targeting CAR T-cell therapy.
  • View the full release here: https://www.businesswire.com/news/home/20240221259676/en/
    Cancer Research UK’s Centre for Drug Development is sponsoring and conducting the Phase 1/2 clinical trial of ALETA-001, the lead agent in Aleta's portfolio.
  • Clinical evaluation of ALETA-001 is a key milestone toward a much-needed treatment option for the many cancer patients whose CD19-targeted CAR T-cell therapies ultimately stop working.

Health On Cloud Expands Global Presence with Innovative Metaverse Medical Platform

Retrieved on: 
Thursday, December 28, 2023

SEOUL, South Korea, Dec. 28, 2023 /PRNewswire/ -- Health On Cloud, an innovator in advanced healthcare solutions, is excited to announce the global expansion of its revolutionary metaverse medical consultation platform, CURISALL, along with its medical education platform, MEDTIS.

Key Points: 
  • SEOUL, South Korea, Dec. 28, 2023 /PRNewswire/ -- Health On Cloud, an innovator in advanced healthcare solutions, is excited to announce the global expansion of its revolutionary metaverse medical consultation platform, CURISALL, along with its medical education platform, MEDTIS.
  • Health On Cloud is focused on deploying a globally connected Virtual University Hospital consisting of (i) Meta-Versity; and (ii) Cloud Hospital.
  • In line with WHO's vision, Health On Cloud envisions creating a world where no one is excluded from medical services.
  • Additionally, by collecting medical data through remote consultations, Health On Cloud aims to contribute to the latest advancements in healthcare technology.

Health On Cloud Expands Global Presence with Innovative Metaverse Medical Platform

Retrieved on: 
Thursday, December 28, 2023

SEOUL, South Korea, Dec. 28, 2023 /PRNewswire/ -- Health On Cloud, an innovator in advanced healthcare solutions, is excited to announce the global expansion of its revolutionary metaverse medical consultation platform, CURISALL, along with its medical education platform, MEDTIS.

Key Points: 
  • SEOUL, South Korea, Dec. 28, 2023 /PRNewswire/ -- Health On Cloud, an innovator in advanced healthcare solutions, is excited to announce the global expansion of its revolutionary metaverse medical consultation platform, CURISALL, along with its medical education platform, MEDTIS.
  • Health On Cloud is focused on deploying a globally connected Virtual University Hospital consisting of (i) Meta-Versity; and (ii) Cloud Hospital.
  • In line with WHO's vision, Health On Cloud envisions creating a world where no one is excluded from medical services.
  • Additionally, by collecting medical data through remote consultations, Health On Cloud aims to contribute to the latest advancements in healthcare technology.

Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Retrieved on: 
Wednesday, December 13, 2023

“Patients and treating physicians have advocated for more research and development in support of LGSOC.

Key Points: 
  • “Patients and treating physicians have advocated for more research and development in support of LGSOC.
  • At Verastem Oncology, we are moving with urgency to offer a Phase 3 study specifically directed at this disease in an effort to address this need,” said Dan Paterson, President and Chief Executive Officer, Verastem Oncology.
  • RAMP 301 is a global trial with enrollment open in the U.S. and planned enrollment in Canada, the United Kingdom, Europe, Australia, and Korea.
  • Dr. Grisham and Dr. Banerjee are paid consultants for Verastem Oncology.

Stallergenes Greer Announces Publication of Positive Results for PALFORZIA® Phase 3 Study in Peanut-allergic Children Aged 1 to 3 Years

Retrieved on: 
Monday, November 20, 2023

Stallergenes Greer, a leading global healthcare company specialising in allergen immunotherapy (AIT), announces the publication of results from the Phase 3 POSEIDON (Peanut Oral Immunotherapy Study of Early Intervention for Desensitization) study in the New England Journal of Medicine Evidence.

Key Points: 
  • Stallergenes Greer, a leading global healthcare company specialising in allergen immunotherapy (AIT), announces the publication of results from the Phase 3 POSEIDON (Peanut Oral Immunotherapy Study of Early Intervention for Desensitization) study in the New England Journal of Medicine Evidence.
  • The study evaluated the efficacy and safety of PALFORZIA [defatted powder of Arachis hypogaea L., semen (peanuts)] in peanut-allergic children aged 1 to 3 years.
  • Overall, 84.7% of patients on PALFORZIA and 93.8% of patients on placebo completed the study.
  • The results, published in the New England Journal of Medicine Evidence, are truly promising and potentially life-changing for young patients.

TMRW Life Sciences Expands Globally Entering UK Fertility Market

Retrieved on: 
Thursday, December 14, 2023

NEW YORK, Dec. 14, 2023 /PRNewswire/ -- TMRW Life Sciences (TMRW), a fertility technology company automating the IVF lab, today announced its global expansion with the adoption of its technology in the United Kingdom (UK). The Hewitt Fertility Centre in Liverpool, England, will become the first clinic outside of the United States to adopt TMRW Life Sciences' CryoRobot Select (CRS), an automated platform for the safe management and storage of frozen eggs and embryos.

Key Points: 
  • NEW YORK, Dec. 14, 2023 /PRNewswire/ -- TMRW Life Sciences (TMRW), a fertility technology company automating the IVF lab, today announced its global expansion with the adoption of its technology in the United Kingdom (UK).
  • The Hewitt Fertility Centre in Liverpool, England, will become the first clinic outside of the United States to adopt TMRW Life Sciences' CryoRobot Select (CRS), an automated platform for the safe management and storage of frozen eggs and embryos.
  • But both efforts are overwhelming the legacy, manual storage systems and laborious hand-labelled identification methods that fertility clinics have relied upon for decades.
  • TMRW received a CE Mark for the CryoRobot Select in September, enabling commercialization across the UK and Europe.

TMRW Life Sciences Expands Globally Entering UK Fertility Market

Retrieved on: 
Thursday, December 14, 2023

NEW YORK, Dec. 14, 2023 /PRNewswire/ -- TMRW Life Sciences (TMRW), a fertility technology company automating the IVF lab, today announced its global expansion with the adoption of its technology in the United Kingdom (UK). The Hewitt Fertility Centre in Liverpool, England, will become the first clinic outside of the United States to adopt TMRW Life Sciences' CryoRobot Select (CRS), an automated platform for the safe management and storage of frozen eggs and embryos.

Key Points: 
  • NEW YORK, Dec. 14, 2023 /PRNewswire/ -- TMRW Life Sciences (TMRW), a fertility technology company automating the IVF lab, today announced its global expansion with the adoption of its technology in the United Kingdom (UK).
  • The Hewitt Fertility Centre in Liverpool, England, will become the first clinic outside of the United States to adopt TMRW Life Sciences' CryoRobot Select (CRS), an automated platform for the safe management and storage of frozen eggs and embryos.
  • But both efforts are overwhelming the legacy, manual storage systems and laborious hand-labelled identification methods that fertility clinics have relied upon for decades.
  • TMRW received a CE Mark for the CryoRobot Select in September, enabling commercialization across the UK and Europe.

Syantra Emerges from Stealth with AI Powered RNA-Based Immune Response Detection Liquid Biopsy Platform and Announces Rob Lozuk as CEO

Retrieved on: 
Wednesday, November 1, 2023

"We are thrilled to add an accomplished world-class executive to our leadership team to elevate our pivotal work in blood-based cancer detection.

Key Points: 
  • "We are thrilled to add an accomplished world-class executive to our leadership team to elevate our pivotal work in blood-based cancer detection.
  • "The existing early cancer detection liquid biopsy paradigm is not adequate, economical, or scalable.
  • Truly disruptive healthcare technologies are generational – and that's exactly what Syantra's liquid biopsy platform will become" states CEO of Syantra, Rob Lozuk, and adds, "I'm thrilled to be joining the Syantra team at this critical juncture in the liquid biopsy arena.
  • Our AI powered RNA-based liquid biopsy platform represents a revolution for the screening and detection modalities by measuring a key shift in the body's immune response that allows cancer to develop.

Volition Presents Breakthrough Liquid Biopsy Blood Test Method for Early-stage Cancer

Retrieved on: 
Monday, October 23, 2023

Volition has developed a novel method for liquid biopsy involving the first reported physical isolation of a class of tumor-derived ctDNA fragments from blood.

Key Points: 
  • Volition has developed a novel method for liquid biopsy involving the first reported physical isolation of a class of tumor-derived ctDNA fragments from blood.
  • Removal of normal DNA obviates expensive and time-consuming DNA sequencing and bioinformatics allowing for rapid, cost-effective detection in a routine blood test."
  • Volition tested the new method in a first small clinical experiment and detected a range of liquid and other cancers, including at early stage I disease.
  • Volition has organized a data insights webinar on Thursday 26th October at 10.30 AM U.S. Eastern to provide more information about the new cancer detection method.